• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Jazz Pharmaceuticals plc - Ordinary Shares (NQ: JAZZ )

    122.97 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 122.97
    Bid (Size) 114.00 (2)
    Ask (Size) 125.00 (1)
    Prev. Close 122.97
    Today's Range 122.97 - 122.97
    52wk Range 99.06 - 134.17
    Shares Outstanding 62,311,104
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NASDAQ:JAZZ is an undervalued gem with solid fundamentals.
    Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents. 
    Via Chartmill
    CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
    The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and... 
    Via Benzinga

    Performance

    YTD
    -3.12%
    -3.12%
    1 Month
    -2.92%
    -2.92%
    3 Month
    +12.83%
    +12.83%
    6 Month
    +11.96%
    +11.96%
    1 Year
    +1.63%
    +1.63%

    More News

    Read More
    Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
    Via Benzinga
    NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Via Chartmill
    FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
    Via Benzinga
    Exposures Product Safety
    NASDAQ:JAZZ, an undervalued stock with good fundamentals.
    Via Chartmill
    In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
    Via Benzinga
    Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
    Via Benzinga
    UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
    Via Benzinga
    Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
    Via The Motley Fool
    Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
    Via Benzinga
    NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Via Chartmill
    Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
    Via Chartmill
    A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
    Via Benzinga
    A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
    Via Benzinga
    FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
    Via Benzinga
    When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    Via Chartmill
    Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
    Via Benzinga
    'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
    Via Benzinga
    The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
    Via Benzinga
    Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
    Via Benzinga
    In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals.
    Via Chartmill
    The 3 Best Cannabis Stocks to Buy in August 2024
    Via InvestorPlace
    Topics Cannabis
    Exposures Cannabis
    3 Biotech Stocks to Buy on the Dip: July 2024
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.